Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment?

Sellmann, Ludger; Fenchel, Klaus; Dempke, Wolfram C M

Sellmann, Ludger; Fenchel, Klaus; Dempke, Wolfram C M.

Afiliação

Sellmann L; 1 Medical Oncology Unit, D-41069 Mönchengladbach, Germany ; 2 Medical Oncology Unit, D-07318 Saalfeld/Saale, Germany ; 3 University of Munich, University Hospital of Grosshadern (Hematology and Oncology), D-81377 Munich, Germany ; 4 AstraZeneca Global Oncology, Cambridge, UK.
Fenchel K; 1 Medical Oncology Unit, D-41069 Mönchengladbach, Germany ; 2 Medical Oncology Unit, D-07318 Saalfeld/Saale, Germany ; 3 University of Munich, University Hospital of Grosshadern (Hematology and Oncology), D-81377 Munich, Germany ; 4 AstraZeneca Global Oncology, Cambridge, UK.
Dempke WC; 1 Medical Oncology Unit, D-41069 Mönchengladbach, Germany ; 2 Medical Oncology Unit, D-07318 Saalfeld/Saale, Germany ; 3 University of Munich, University Hospital of Grosshadern (Hematology and Oncology), D-81377 Munich, Germany ; 4 AstraZeneca Global Oncology, Cambridge, UK.

Transl Lung Cancer Res ; 4(3): 223-7, 2015 Jun.

Article em En | MEDLINE | ID: mdl-26207209

Palavras-chave

Gefitinib; editorial; maintenance therapy; non-small-cell lung cancer (NSCLC); overall survival (OS)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Pulmao Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: Transl Lung Cancer Res Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google